{"id":"W2722759707","doi":"10.1200/jco.2017.35.15_suppl.e13525","title":"BBI608-201GBM: A phase Ib/II clinical study of napabucasin (BBI608) in combination with temozolomide (TMZ) for adult patients with recurrent glioblastoma (GBM).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Nausea; Tolerability; Internal medicine; Temozolomide; Oncology; Cancer; Bevacizumab; Pharmacology; Gastroenterology; Adverse effect; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005532382,0.0003254115,0.00204663,0.000225311,0.000403241,0.00002850788,0.0008071174,0.0006578359,0.0000845498],"category_scores_gemma":[0.003790908,0.0002067007,0.0003508613,0.0001549051,0.00089362,0.0003626411,0.0001909826,0.002067471,0.000004786835],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001324384,"about_ca_system_score_gemma":0.0008173445,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002303507,"about_ca_topic_score_gemma":0.0008910468,"domain_scores_codex":[0.9932849,0.00178492,0.003562382,0.0004658249,0.0004438575,0.0004580784],"domain_scores_gemma":[0.9876443,0.002989955,0.006340353,0.0003961147,0.002180934,0.0004483856],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.09277454,0.07311734,0.6616358,0.00004344701,0.0008819151,0.0002093091,0.0003326054,0.00001531069,0.00002935949,0.0001130145,0.003117141,0.1677303],"study_design_scores_gemma":[0.147429,0.2175767,0.60151,0.0001612637,0.0007342104,0.00003227523,0.000456198,0.0005341942,0.0001316017,0.0001883985,0.03094649,0.0002996866],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924723,0.00004746129,0.00009382258,0.002159986,0.003353493,0.001384227,0.00004807766,0.00001006951,0.0004305847],"genre_scores_gemma":[0.9974617,0.0001628516,0.0007912014,0.0008815081,0.000528501,0.00003444854,0.000007707102,0.00003252111,0.00009955376],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1674306,"threshold_uncertainty_score":0.8982249,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2930263292070344,"score_gpt":0.5846921575951359,"score_spread":0.2916658283881016,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}